ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS

(19)

(11)

EP 3 363 797 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	28.04.2021 Bulletin 2021/17

(43)	Date of publication:
	22.08.2018 Bulletin 2018/34

(21)	Application number: 17208659.7

(22)	Date of filing: 12.07.2010

(51)

International Patent Classification (IPC):

C07D 401/12^(2006.01)
C07D 407/14^(2006.01)
C07D 471/04^(2006.01)
A61K 31/437^(2006.01)
A61K 31/444^(2006.01)
A61K 31/506^(2006.01)
A61P 25/28^(2006.01)
A61P 37/00^(2006.01)
A61K 31/5377^(2006.01)
A61K 31/4709^(2006.01)

C07D 401/14^(2006.01)
C07D 413/14^(2006.01)
C07D 491/048^(2006.01)
A61K 31/4439^(2006.01)
A61K 31/497^(2006.01)
A61P 9/00^(2006.01)
A61P 29/00^(2006.01)
A61K 31/585^(2006.01)
A61K 31/496^(2006.01)
A61K 45/06^(2006.01)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30)

Priority:

13.07.2009 US 225076 P
13.07.2009 US 225079 P
22.12.2009 US 289263 P

(60)	Divisional application:
	20210819.7

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	15151030.2 / 2933252
	10733116.7 / 2454250

(71)	Applicant: Gilead Sciences, Inc.
	Foster City, CA 94404 (US)

(72)	Inventors:
	CORKEY, Britton Foster City, CA 94404 (US) GRAUPE, Michael Pacifica CA 94044 (US) KOCH, Keith Erie CO 80516 (US) MELVIN, Lawrence S. Longmont CO 80504 (US) NOTTE, Gregory San Mateo CA 9441 (US)

(74)	Representative: Wallace, Sheila Jane
	Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW London EC4A 1BW (GB)


	Remarks:
	This application was filed on 19-12-2017 as a divisional application to the application mentioned under INID code 62.


	Remarks:
	Claims filed after the date of filing of the application/after the date of receipt of the divisional application (Rule 68(4) EPC).

(54)	ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS

(57) The present invention relates to compounds of Formula (I): wherein X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, R¹, R², R³ are as defined above. The compounds have apoptosis signal-regulating kinase ("ASK1") inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).